Advanced search

Epidemiological and Economic Impact of Human Papillomavirus Vaccines

Sarah Jeurissen (UGent) and Amin Makar (UGent)
Author
Organization
Abstract
Background: Despite screening, cervical cancer (CC) remains a serious health care problem. Because human papillomavirus (HPV) is the necessary cause of CC, the development of 2 new vaccines can have a tremendous impact oil CC and other HPV-related conditions. In this systematic review, the epidemiological and economic impacts of HPV are evaluated. Methods: A literature search was conducted through MEDLINE, Web of Science, Cochrane Library, and Cumulative Index to Nursing and Allied Health Literature. Articles were selected based on inclusion and exclusion criteria. Economic evaluations were submitted to a quality assessment. Results: Sixteen articles were selected to review the epidemiological impact of HPV vaccines, and 11 were selected to review the economic impact. The studies were very heterogeneous because of different assumptions. Nevertheless, a substantial reduction in CC is reported consistently and a (smaller) reduction in precancerous lesions and HPV prevalence. Cost-effectiveness ratios are also very diverse and dependent oil the assumptions made. An HPV vaccine can be profitable if duration of vaccine-related immunity is high, efficacy is high, price is low, screening is reduced, administration is before sexual activity, discount rate is not too high, or if there is herd immunity. Conclusions: Human papillomavirus vaccines have the potential to reduce CC by at least approximately half of its current incidence, and this might be cost-effective if there is high efficacy with a long-lasting immunity.
Keywords
TRIAL, EFFICACY, PROGRAMS, POPULATION-LEVEL IMPACT, COST-EFFECTIVENESS ANALYSIS, CERVICAL-CANCER, PARTICLE VACCINE, STRATEGIES, TYPE-16

Citation

Please use this url to cite or link to this publication:

Chicago
Jeurissen, Sarah, and Amin Makar. 2009. “Epidemiological and Economic Impact of Human Papillomavirus Vaccines.” International Journal of Gynecological Cancer 19 (4): 761–771.
APA
Jeurissen, S., & Makar, A. (2009). Epidemiological and Economic Impact of Human Papillomavirus Vaccines. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 19(4), 761–771.
Vancouver
1.
Jeurissen S, Makar A. Epidemiological and Economic Impact of Human Papillomavirus Vaccines. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS; 2009;19(4):761–71.
MLA
Jeurissen, Sarah, and Amin Makar. “Epidemiological and Economic Impact of Human Papillomavirus Vaccines.” INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19.4 (2009): 761–771. Print.
@article{847524,
  abstract     = {Background: Despite screening, cervical cancer (CC) remains a serious health care problem. Because human papillomavirus (HPV) is the necessary cause of CC, the development of 2 new vaccines can have a tremendous impact oil CC and other HPV-related conditions. In this systematic review, the epidemiological and economic impacts of HPV are evaluated.
Methods: A literature search was conducted through MEDLINE, Web of Science, Cochrane Library, and Cumulative Index to Nursing and Allied Health Literature. Articles were selected based on inclusion and exclusion criteria. Economic evaluations were submitted to a quality assessment.

Results: Sixteen articles were selected to review the epidemiological impact of HPV vaccines, and 11 were selected to review the economic impact. The studies were very heterogeneous because of different assumptions. Nevertheless, a substantial reduction in CC is reported consistently and a (smaller) reduction in precancerous lesions and HPV prevalence. Cost-effectiveness ratios are also very diverse and dependent oil the assumptions made. An HPV vaccine can be profitable if duration of vaccine-related immunity is high, efficacy is high, price is low, screening is reduced, administration is before sexual activity, discount rate is not too high, or if there is herd immunity.

Conclusions: Human papillomavirus vaccines have the potential to reduce CC by at least approximately half of its current incidence, and this might be cost-effective if there is high efficacy with a long-lasting immunity.},
  author       = {Jeurissen, Sarah and Makar, Amin},
  issn         = {1048-891X},
  journal      = {INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER},
  language     = {eng},
  number       = {4},
  pages        = {761--771},
  publisher    = {LIPPINCOTT WILLIAMS \& WILKINS},
  title        = {Epidemiological and Economic Impact of Human Papillomavirus Vaccines},
  url          = {http://dx.doi.org/10.1111/IGC.0b013e3181a130c0},
  volume       = {19},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: